EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling Cathepsin B inhibition with repurposed drugs for anticancer and anti-Alzheimer’s drug discovery

Mohammed Alrouji, Sabina Yasmin iD, Mohammed S Alshammari, Fahad A Alhumaydhi iD, Sharaf E Sharaf iD, Moyad Shahwan, Anas Shamsi iD

PLOS ONE · 19.12.2024 · 19 (12) · e0316010

DOI: 10.1371/journal.pone.0316010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 19.12.2024. Verfasst von Mohammed Alrouji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia. Hauptthemen laut MEDLINE: Cathepsin B, Alzheimer Disease, Drug Repositioning, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Khalid University, Ajman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is characterized by the aggregation of amyloid β (Aβ) peptides and the formation of plaques in the brain, primarily derived from the proteolytic degradation of amyloid precursor protein (APP). Cathepsin B (CatB) is a cysteine protease that plays a pivotal role in this process, making it a potential target for the development of anti-Alzheimer’s therapies. Apart from AD, CatB is implicated in various physiological and pathological processes, including cancer. Given the critical role of CatB in these diseases, identifying effective inhibitors is of significant therapeutic interest. In this study, we employed a systematic virtual screening approach using repurposed molecules from the DrugBank database to identify potential CatB inhibitors. Primarily, we focused on binding affinities and selectivity to pinpoint potential hits against CatB. Two repurposed molecules, Lurasidone and Paliperidone, emerged as promising candidates with significant affinity for CatB. These molecules demonstrated favorable drug profiles and exhibited preferential binding to the catalytic pocket of CatB via interacting with functionally significant residues. To further explore the binding mechanism and stability of the CatB-drug complexes, molecular dynamics (MD) simulations were conducted for 500 ns. The results revealed that CatB and Lurasidone, as well as Paliperidone, form stable complexes throughout the simulation. Taken together, the findings suggest that Lurasidone and Paliperidone can act as repurposed CatB inhibitors with potential applications in the development of therapeutics against AD and other CatB-associated diseases after further validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cathepsin BAlzheimer DiseaseDrug RepositioningAntineoplastic AgentsMolecular Dynamics SimulationDrug DiscoveryHumansMolecular Docking SimulationProtein Binding

Substanzen

Cathepsin BAntineoplastic AgentsCTSB protein, human

Autor:innen und Institutionen

  • Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
  • Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
  • Pharmaceutical Sciences Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Center of Medical and Bio-Allied Health Sciences Research (CMBHSR), Ajman University, Ajman, United Arab Emirates.

ORCID-Profile: Sabina Yasmin, Fahad A Alhumaydhi, Sharaf E Sharaf, Anas Shamsi

Förderung

  • King Khalid University
  • Ajman University

Zitieren

APA

Alrouji, M., Yasmin, S., Alshammari, M. S., Alhumaydhi, F. A., Sharaf, S. E., Shahwan, M., & Shamsi, A. (2024). Unveiling Cathepsin B inhibition with repurposed drugs for anticancer and anti-Alzheimer’s drug discovery. PLOS ONE, 19(12), e0316010. https://doi.org/10.1371/journal.pone.0316010

Vancouver

Alrouji M, Yasmin S, Alshammari MS, Alhumaydhi FA, Sharaf SE, Shahwan M, et al. Unveiling Cathepsin B inhibition with repurposed drugs for anticancer and anti-Alzheimer’s drug discovery. PLOS ONE. 2024;19(12):e0316010. doi:10.1371/journal.pone.0316010

BibTeX
@article{Alrouji2024,
  author = {Alrouji, Mohammed and Yasmin, Sabina and Alshammari, Mohammed S and Alhumaydhi, Fahad A and Sharaf, Sharaf E and Shahwan, Moyad and Shamsi, Anas},
  title = {Unveiling Cathepsin B inhibition with repurposed drugs for anticancer and anti-Alzheimer’s drug discovery},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {12},
  pages = {e0316010},
  doi = {10.1371/journal.pone.0316010}
}
Kostenlos starten →